Eton Pharmaceutical ETON 深 滬
交易中 12-24 10:08:03 美东时间
16.655
+0.105
+0.63%
華盛通- 最 高16.77
- 今 開16.64
- 成交量 5737股
- 最 低 16.56
- 昨 收 16.55
- 總市值 4.47亿
- 52周最高 23.00
- 市盈率 靜 --
- 換手率 0.02%
- 52周最低 11.0867
- 委 比 -66.72%
- 總股本 2681.75万
- 歷史最高 23.00
- 量 比 0.51
- 振 幅 1.27%
- 歷史最低 1.95
- 每 手 1
- 風險率 2.18%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Eton Pharmaceuticals Joins Piper Sandler Healthcare Conference
The latest announcement is out from Eton Pharmaceuticals ( ($ETON) ). On Decemb...
12-04 20:58
Eton Pharmaceuticals to Present at Piper Sandler 37th Annual Healthcare Conference on December 4th
Eton Pharmaceuticals announced that its executive leadership team will host a fireside chat at the Piper Sandler 37th Annual Healthcare Conference in NYC on December 4, 2025, at 9:30 AM ET. The Company, focused on rare disease treatments, currently has eight commercial products and five late-stage product candidates. For更多信息, please visit www.etonpharma.com.
11-24 21:30
电话会总结 ｜ Eton Pharma(ETON)2025财年Q3业绩电话会核心要点
<span style="color:#999999;">编者按：聚焦公司高管观点与展望，深挖业绩背后的信息，助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• 根据Eton Pharmaceuticals业绩会实录，以下是Q3 2025财务业绩回顾摘要： ## 1. 财务业绩 **营收表现：** Q3 2025产品收入达2,250万美元，同比增长129%，环比增长19%，实现连续第19个季度的环比增长。增长主要由Alkindi Sprinkle、kerglumic acid以及新收购的Incralex和Galzin产品驱动。 **盈利能力：** 调整后毛利润为1,020万美元，调整后毛利率为45%，较去年同期的64%有所下降。调整后EBITDA为290万美元，较去年同期的200万美元有所改善。 **净利润：
11-10 12:05
Eton Pharmaceuticals shares are trading lower after the company reported mixed Q3 financial results.
Eton Pharmaceuticals shares are trading lower after the company reported mixed ...
11-07 06:21
Earnings Scheduled For November 6, 2025
Companies Reporting Before The Bell • Clear Channel Outdoor (NYSE:CCO) is expec...
11-06 19:12
PMV Pharmaceuticals Announces Updated Data From The Phase 2 Pivotal Portion Of The Ongoing PYNNACLE Clinical Trial In Patients With Advanced Solid Tumors Harboring A TP53 Y220C Mutation; Overall Response Rate Of 34% (35/103 Patients) Per Investigator Assessment According To Response Evaluation Criteria In Solid Tumors (RECIST) Version 1.1, Including Confirmed And Unconfirmed Responses
Data presented today as an oral presentation at 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Confirmed responses observed in eight tumor types spanning ovarian, lung,
10-24 23:44
Soligenix Updates U.S. Medical Advisory Board To Guide Phase 3 HyBryte Development For CTCL
Providing Strategic Medical Guidance in Advancing HyBryte™ Clinical DevelopmentPRINCETON, N.J., Oct. 14, 2025 /PRNewswire/ -- Soligenix, Inc. (NASDAQ:SNGX) (Soligenix or the Company), a late-stage
10-14 19:33
Soligenix Expands European MAB To Provide Addl Medical/Clinical Strategic Guidance As It Advances Confirmatory Phase 3 Placebo-Controlled Study Evaluating Safety And Efficacy Of HyBryte In CTCL Treatment
In preparation for health authority interactions in pursuit of marketing approvals in Europe PRINCETON, N.J., Sept. 30, 2025 /PRNewswire/ -- Soligenix, Inc. (NASDAQ:SNGX) (Soligenix or the Company), a
09-30 19:36
Soligenix Announces Pricing of $7.5 Million Public Offering
PRINCETON, N.J., Sept. 26, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) ("Soligenix" or the "Company"), a late-stage biopharmaceutical company focused on developing and commercializin...
09-26 18:33
PDS Biotech Reports 29.5-Month Median Overall Survival In Phase 2 Trial For Advanced Head And Neck Cancer; Says Encouraging Efficacy Signal Observed In Difficult To Treat Category Of Advanced Head And Neck Cancer Patients
First combination therapy to report 29.5 months of Median Overall Survival (mOS); Standard of care Keytruda® (pembrolizumab) alone (10.8 months) and Keytruda® + chemotherapy (12.3 months) in patients with CPS
09-18 20:47
